138 related articles for article (PubMed ID: 29157102)
1. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.
Li JA; Song C; Rong Y; Kuang T; Wang D; Xu X; Yuan J; Luo K; Qin B; Nowsheen S; Lou Z; Lou W
Cell Cycle; 2018; 17(2):191-199. PubMed ID: 29157102
[TBL] [Abstract][Full Text] [Related]
2. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
[TBL] [Abstract][Full Text] [Related]
4. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
[TBL] [Abstract][Full Text] [Related]
5. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
6. MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis.
Wu MH; Lee CY; Huang TJ; Huang KY; Tang CH; Liu SH; Kuo KL; Kuan FC; Lin WC; Shi CS
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586948
[TBL] [Abstract][Full Text] [Related]
7. MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death.
Hu L; Bai ZG; Ma XM; Bai N; Zhang ZT
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8273-8280. PubMed ID: 30556867
[TBL] [Abstract][Full Text] [Related]
8. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor.
Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y
Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810
[TBL] [Abstract][Full Text] [Related]
9. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Lan H; Tang Z; Jin H; Sun Y
Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
[TBL] [Abstract][Full Text] [Related]
10. Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis.
Zheng W; Luo Z; Zhang J; Min P; Li W; Xu D; Zhang Z; Xiong P; Liang H; Liu J
Mol Med Rep; 2017 May; 15(5):2795-2801. PubMed ID: 28447739
[TBL] [Abstract][Full Text] [Related]
11. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
[TBL] [Abstract][Full Text] [Related]
12. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma.
Zhang Y; Shi CC; Zhang HP; Li GQ; Li SS
Oncotarget; 2016 Jul; 7(29):45263-45274. PubMed ID: 27223074
[TBL] [Abstract][Full Text] [Related]
13. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
Urrutia G; Salmonson A; Toro-Zapata J; de Assuncao TM; Mathison A; Dusetti N; Iovanna J; Urrutia R; Lomberk G
Mol Cancer Res; 2020 Mar; 18(3):448-462. PubMed ID: 31822519
[TBL] [Abstract][Full Text] [Related]
14. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
[TBL] [Abstract][Full Text] [Related]
15. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
[TBL] [Abstract][Full Text] [Related]
16. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
Jazaeri AA; Shibata E; Park J; Bryant JL; Conaway MR; Modesitt SC; Smith PG; Milhollen MA; Berger AJ; Dutta A
Mol Cancer Ther; 2013 Oct; 12(10):1958-67. PubMed ID: 23939375
[TBL] [Abstract][Full Text] [Related]
17. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
[TBL] [Abstract][Full Text] [Related]
18. MLN4924 therapy as a novel approach in cancer treatment modalities.
Oladghaffari M; Islamian JP; Baradaran B; Monfared AS
J Chemother; 2016 Apr; 28(2):74-82. PubMed ID: 26292710
[TBL] [Abstract][Full Text] [Related]
19. The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
Bahjat M; de Wilde G; van Dam T; Maas C; Bloedjes T; Bende RJ; van Noesel CJM; Luijks DM; Eldering E; Kersten MJ; Guikema JEJ
Cell Cycle; 2019 Sep; 18(18):2307-2322. PubMed ID: 31349760
[TBL] [Abstract][Full Text] [Related]
20. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
Cooper J; Xu Q; Zhou L; Pavlovic M; Ojeda V; Moulick K; de Stanchina E; Poirier JT; Zauderer M; Rudin CM; Karajannis MA; Hanemann CO; Giancotti FG
Mol Cancer Ther; 2017 Aug; 16(8):1693-1704. PubMed ID: 28468780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]